Calithera Biosciences, Inc. (CALA) Analysts See $-0.33 EPS

July 14, 2018 - By Mona Holcomb

Calithera Biosciences, Inc. (NASDAQ:CALA) LogoInvestors sentiment decreased to 0.91 in Q1 2018. Its down 1.29, from 2.2 in 2017Q4. It is negative, as 16 investors sold Calithera Biosciences, Inc. shares while 29 reduced holdings. 10 funds opened positions while 31 raised stakes. 21.05 million shares or 12.94% less from 24.18 million shares in 2017Q4 were reported.
Morgan Stanley invested in 68,845 shares. Citadel Advisors Ltd Liability Corp stated it has 73,682 shares. 1.42 million were reported by Federated Invsts Pa. Wells Fargo & Mn invested in 0% or 65,566 shares. Point72 Asia (Hong Kong) Ltd holds 0.01% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 2,447 shares. Jpmorgan Chase And accumulated 6,167 shares. Legal & General Gp Pcl holds 0% or 5,432 shares in its portfolio. Cubist Systematic Strategies Limited Liability Corp holds 0.01% or 32,402 shares. Dimensional Fund Advsrs Limited Partnership reported 0% stake. Royal Comml Bank Of Canada holds 0% in Calithera Biosciences, Inc. (NASDAQ:CALA) or 6,411 shares. Fmr Ltd Liability Co, a Massachusetts-based fund reported 680,710 shares. Bluemountain Mgmt Limited Liability has invested 0.01% in Calithera Biosciences, Inc. (NASDAQ:CALA). Millennium Mngmt Limited Liability Co holds 713,131 shares or 0.01% of its portfolio. Stratos Wealth Ptnrs Ltd reported 715 shares. Ubs Asset Mngmt Americas Incorporated stated it has 0% in Calithera Biosciences, Inc. (NASDAQ:CALA).

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.33 EPS on August, 14.They anticipate $0.18 EPS change or 120.00 % from last quarter’s $-0.15 EPS. After having $-0.37 EPS previously, Calithera Biosciences, Inc.’s analysts see -10.81 % EPS growth. The stock decreased 2.06% or $0.1 during the last trading session, reaching $4.75. About 162,094 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 65.69% since July 14, 2017 and is downtrending. It has underperformed by 78.26% the S&P500.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $170.26 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Another recent and important Calithera Biosciences, Inc. (NASDAQ:CALA) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial” on July 12, 2018.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: